Description: At the conclusion of the first part, attendees will be able to describe sources of reserve redundancy for products under Principle Based Reserve (PBR) and products under Commissioners' Annuity Reserve Valuation Method (CARVM). Such products include Term Life, Whole Life, Universal Life, and Fixed Annuity with and without rider. We will also review sources of capital redundancy from the C-1 factor under Risk-Based Capital (RBC) and assets such as Unrated Asset Credit Fund can have high C-1 factor even if its risks are limited. At the conclusion of the second part, the attendees will learn about potential Reserve Relief reinsurance solutions. Such solutions can provide Reserve Relief for annuity and term life businesses, as well as potential innovative asset-side solutions. Asset managers can structure assets that the C-1 factor aligned with the corresponding risk.

Description: Renal disease is a very heterogenous medical condition whose end state is dialysis, a recurring cost intensive medical condition. Dialysis cost is one of the major medical cost drivers in USA. Insufficient and improper care management in the early stages of CKD (chronic kidney disease) leads to early incidence of end stage renal disease (ESRD) among CKD patients which not only leads to high medical costs, but also reflects poor health quality.

Description: Hear about the new hope biosimilars bring in helping payers and patients manage the rapidly growing pharmacy spend. The Big Event, encompassing multiple Humira biosimilars, launches in 2023 and could set the tone for how much biosimilars can be expected to contribute to solving our pharmacy spend challenges. What will be the financial impact of the Big Event and this coming wave? What can be done to maximize adoption of biosimilars? What strategies are available to maximize savings for payers and patients?

Description: Explore wellness programs and their effectiveness within the LTC industry by attending the Considerations for LTC Wellness Programs webcast. You will experience discussions about design tactics and evaluation processes for programs, as well as discovering ways to assist policyholders achieve a sustainable and equitable life. There will also be a conversation about the current regulatory environment as it relates to LTC wellness programs. This webinar will focus on subsets of insured populations that are high risk of claim in order to properly manage care decisions and ensure unfair bias is avoided. Learn how to test for unfair bias and determine best possibilities on how to guard against this when testing is unavailable.

Description: With mortality rates significantly higher in 2020 and 2021 due to the COVID-19 pandemic, actuaries that rely on historical experience cannot properly craft assumptions about the future due to the recent excess deaths. This webcast focuses on the practicality of using pandemic mortality experience, as well as how to overcome the practical challenges of that data implementation. Explore an overview of different approaches used by institutions in the U.S., Canada and UK and an observation of industry survey responses. There will also be a comparison to recent SOA expert opinion surveys and short term impacts on the future of U.S. mortality.

Description: Come learn from a panel of LTC industry professionals as they discuss setting goals for LTC wellness, measuring success of the programs, and integrating them with other LTC process (e.g. assumption setting) in an effort to create sustainable programs.

Description: Reinsurance discussions around blocks of long-term care (LTC) have been going on for years without many deals being consummated. However, in 2023 the action picked up and we saw the largest inforce LTC reinsurance deal ever announced. Will this open the floodgates to more LTC deals? This webinar will provide background on legacy LTC blocks, the challenges they have faced, and why they may be now ripe for transactions. We will explore views from both buyers and sellers. The webinar will examine how sellers can best position their LTC blocks for a transaction. We will also look at the motivations of buyers and what might be drawing them to LTC blocks now.

Description: Hot Topics in Setting Pension Return Assumptions is the third in a series, following Mathematics of Pension Return Assumption and Inflation, focusing on Effects, Forecasts, and Role in Pension Valuations. What time horizon is more appropriate for Capital Market Assumption (CMA) forecasts: mid-term or long-term time horizon, or a blend of both? How do we map the asset classes of a plan's own investment policy to the asset classes of investment forecasters' CMAs? If we use asset-smoothing for valuation assets, should we use market-driven expected returns or smoothed/average versions of them?

Description: Dedicated to those interested in the approaches of long-term pension assets, the How Should Long-Term Pension Assets Be Invested? A Debate webcast allows you to focus on where to devote your pension attention. Participants in this panel concentrate on perspectives and opinions on the direction of long-term pension assets. Expand your viewpoint on the investment of long-term pension assets by discovering other ideas about the industry. Determine how to handle your association with these assets and how to make the best move for the retirement business.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.